組織概要

GOTIC-014 PAOLA-1 /
GINECO-OV125b 試験
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. Ray-Coquard I, Pautier P, Pignata S, Pe´rol D, Gonza´lez-Marti´n A, Berger R, Fujiwara K, Vergote I, Colombo N, Ma¨enpa¨a¨ J, Selle F, Sehouli J, Lorusso D, Guerra Ali´a E M, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marme´ F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P. N Engl J Med 2019 Dec; 381:2416-2428. Doi:10.1056/NEJMoa1911361
GOTIC-003
iPLAS 試験
A phaseUrandomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer. (GOTIC003/intergroup study)
Fujiwara H, Ushijima K, Nagao S, Takei Y, Shimada M, Takano M, Yoshino K, Kawano Y, Hirashima Y, Nagase S, Nishio S, Nishikawa T, Ito K, Shoji T, Kimura E, Takano T, Sugiyama T, Kigawa J, Fujiwara K, Suzuki M. Int. J. Clin Oncol. 2019 Oct; 24(10):1284-1291. doi: 10.1007/s10147-019-01471-5
GOTIC-012 / ANZGOG 0701
Symptom Benefit試験
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.
Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M. Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.
2017.10.019. Epub 2017 Oct 26.

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group.
Oncologist. 2017 Sep;22(9):1117-1124. doi: 10.1634/theoncologist.2017-0047 Epub 2017 Jun 8.
GOTIC-006
後方視的研究
Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors. (GOTIC Study) Nakamura K, Kitahara Y, Satoh T, Takei Y, Takano M, Nagao S, Sekiguchi I, Suzuki M. World J Surg Oncol. 2016;14:173. doi: 10.1186/s12957-016-0931-4
GOTIC-007
後方視的研究
Evaluation of endometrial cytology: cytohistological correlations in 1,441 cancer patients. Fujiwara H, Takahashi Y, Takano M, Miyamoto M, Nakamura K, Kaneta Y, Hanaoka T, Ohwada M, Sakamoto T, Hirakawa T, Fujiwara K, Suzuki M. Oncology. 2015;88(2):86-94. doi: 10.1159/000368162
GCIG Rare Tumor Consensus ReviewGynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-S95. doi: 10.1097/IGC.0000000000000297
GCIG Rare Tumor Consensus ReviewGynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Fujiwara H, Yokota H, Monk B. Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-S101. doi: 10.1097/IGC.0000000000000263
GCIG Rare Tumor Consensus ReviewGynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, Pautier P, Reed NS, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-S108. doi: 10.1097/IGC.0000000000000262
GOITC-005
後方視的研究
Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Takano M, Ochi H, Takei Y, Miyamoto M, Hasumi Y, Kaneta Y, Nakamura K, Kurosaki A, Satoh T, Fujiwara H, Nagao S, Furuya K, Yokota H, Ito K, Minegishi T, Yoshikawa H, Fujiwara K, Suzuki M. Br J Cancer. 2013 Oct 1;109(7):1760-1765. doi: 10.1038/bjc.2013.521
SGSG-012/
GOITC-004
後方視的研究
Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study. Nagao S, Nishio S, Michimae H, Tanabe H, Okada S, Otsuki T, Tanioka M, Fujiwara K, Suzuki M, Kigawa J. Gynecol Oncol. 2013 Dec;131(3):567-573. doi: 10.1016/j.ygyno.2013.09.021

↑ページトップに戻る↑